These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 31303756)

  • 1. Long-term efficacy and safety of paliperidone palmitate once-monthly in Chinese patients with recent-onset schizophrenia.
    Si T; Zhuo J; Feng Y; Lu H; Hong D; Zhang L
    Neuropsychiatr Dis Treat; 2019; 15():1685-1694. PubMed ID: 31303756
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study.
    Zhao J; Li L; Shi J; Li Y; Xu X; Li K; Zhang L; Cai S; Feng Y; Zhuo J; Liu W; Lu H
    Neuropsychiatr Dis Treat; 2017; 13():2045-2056. PubMed ID: 28814873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study.
    Savitz AJ; Xu H; Gopal S; Nuamah I; Ravenstijn P; Hough D; Mathews M; Feng Y; Yu L; Takahashi M; Liu D; Wang G; Yoon JS; Chen JJ
    Neuropsychiatr Dis Treat; 2017; 13():2193-2207. PubMed ID: 28860777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia.
    Zhang F; Si T; Chiou CF; Harris AW; Kim CY; Jahagirdar P; Ascher S
    Neuropsychiatr Dis Treat; 2015; 11():657-68. PubMed ID: 25792835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.
    Li H; Rui Q; Ning X; Xu H; Gu N
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):1002-8. PubMed ID: 21315787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study.
    Savitz AJ; Xu H; Gopal S; Nuamah I; Ravenstijn P; Janik A; Schotte A; Hough D; Fleischhacker WW
    Int J Neuropsychopharmacol; 2016 Jul; 19(7):. PubMed ID: 26902950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional study.
    Schreiner A; Caspi A; Bergmans P; Cherubin P; Keim S; Lara E; Pinchuk I; Schuepbach D; Suleman S; Hargarter L
    Psychopharmacology (Berl); 2017 Jan; 234(1):3-13. PubMed ID: 27815602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate.
    Mathews M; Nuamah I; Savitz AJ; Hough DW; Najarian D; Kim E; Gopal S
    Neuropsychiatr Dis Treat; 2018; 14():2807-2816. PubMed ID: 30498351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intramuscular long-acting paliperidone palmitate in acute patients with schizophrenia unsuccessfully treated with oral antipsychotics.
    Hargarter L; Cherubin P; Bergmans P; Keim S; Rancans E; Bez Y; Parellada E; Carpiniello B; Vidailhet P; Schreiner A
    Prog Neuropsychopharmacol Biol Psychiatry; 2015 Apr; 58():1-7. PubMed ID: 25448776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of once-monthly injection of paliperidone palmitate in hospitalized Asian patients with acute exacerbated schizophrenia: an open-label, prospective, noncomparative study.
    Li H; Turkoz I; Zhang F
    Neuropsychiatr Dis Treat; 2016; 12():15-24. PubMed ID: 26730193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Symptomatic and functional outcomes after treatment with paliperidone palmitate 3-month formulation for 52 weeks in patients with clinically stable schizophrenia.
    Garcia-Portilla MP; Llorca PM; Maina G; Bozikas VP; Devrimci-Ozguven H; Kim SW; Bergmans P; Usankova I; Pungor K
    Ther Adv Psychopharmacol; 2020; 10():2045125320926347. PubMed ID: 32518617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An open-treatment six-week study of the clinical effectiveness of Paliperidone Palmitate in schizophrenia: data from acute units in Spain (SHADOW study).
    Parellada E; Bioque M; Serrano M; Herrera B; García Dorado M;
    Int J Psychiatry Clin Pract; 2018 Sep; 22(3):191-199. PubMed ID: 29161951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia: A Randomized Clinical Trial.
    Berwaerts J; Liu Y; Gopal S; Nuamah I; Xu H; Savitz A; Coppola D; Schotte A; Remmerie B; Maruta N; Hough DW
    JAMA Psychiatry; 2015 Aug; 72(8):830-9. PubMed ID: 25820612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Paliperidone Palmitate 6-Month versus Paliperidone Palmitate 3-Month Long-Acting Injectable in European Patients with Schizophrenia: A Post Hoc Analysis of a Global Phase-3 Double-Blind Randomized Non-Inferiority Study.
    Giron-Hernandez C; Han JH; Alberio R; Singh A; García-Portilla MP; Pompili M; Knight RK; Richarz U; Gopal S; Antunes J
    Neuropsychiatr Dis Treat; 2023; 19():895-906. PubMed ID: 37077705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paliperidone Palmitate Once-Monthly Injectable Treatment for Acute Exacerbations of Schizoaffective Disorder.
    Fu DJ; Turkoz I; Simonson RB; Walling D; Schooler N; Lindenmayer JP; Canuso C; Alphs L
    J Clin Psychopharmacol; 2016 Aug; 36(4):372-6. PubMed ID: 27322760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Once-monthly injection of paliperidone palmitate in patients with recently diagnosed and chronic schizophrenia: a post-hoc comparison of efficacy and safety.
    Si T; Zhuo J; Turkoz I; Mathews M; Tan W; Feng Y
    Expert Opin Pharmacother; 2017 Dec; 18(17):1799-1809. PubMed ID: 29141463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of once-monthly paliperidone palmitate long-acting injection in an elderly patient with schizophrenia.
    Rama Raj P; Lewis M; Macfarlane S
    BMJ Case Rep; 2015 Aug; 2015():. PubMed ID: 26311017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of paliperidone extended-release in Chinese patients with schizophrenia: a 24-week, open-label extension of a randomized, double-blind, placebo-controlled study.
    Zhang H; Li H; Liu Y; Wu C; Wu Q; Nuamah I; Shi J; Xie S; Wang G; Gopal S
    Neuropsychiatr Dis Treat; 2016; 12():69-77. PubMed ID: 26811679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia.
    Gopal S; Vijapurkar U; Lim P; Morozova M; Eerdekens M; Hough D
    J Psychopharmacol; 2011 May; 25(5):685-97. PubMed ID: 20615933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens.
    Fu DJ; Bossie CA; Kern Sliwa J; Ma YW; Alphs L
    Clin Schizophr Relat Psychoses; 2014 Jul; 8(2):101-9, 109A. PubMed ID: 23446197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.